- George Zimmerman will not be charged in domestic dispute
- Russian officials press bilateral U.S. trade deal
- Selfies at Funerals blog creator retires after Obama flub: ‘Our work here is done’
- New Obama adviser Podesta is against Keystone but will steer clear of pipeline deliberations
- 40 Australian adults, children found in ‘one of the worst accounts of incest ever made public’
- Venezuela’s Maduro calls on student ‘price vigilantes’ to hit the streets, report businesses
- Atheists smug as Hindus join Satanists to demand display at Oklahoma Statehouse
- Bow before Valkyrie, NASA’s ‘superhero robot’ entry in DARPA challenge
- 10-year-old Pennsylvania boy suspended for pretend bow-and-arrow shooting
- Tea partiers turn on Capitol Hill budget deal
Merck: FDA won’t OK its combo cholesterol drug now
TRENTON, N.J. (AP) - Federal regulators have rejected Merck & Co.'s new combination cholesterol drug, which includes a generic version of the mega-blockbuster Lipitor _ at least for now.
It's unclear how long the ruling, announced Monday, might delay approval of the drug, as the Food and Drug Administration is requiring additional study data on the compound. It combines generic Lipitor, the top-selling drug of all time, with Merck's cholesterol medicine Zetia.
Approval could boost Merck's sagging cholesterol franchise by essentially replacing its existing combo pill, Vytorin, with one likely to be seen as more powerful. Vytorin sales have been dwindling for a few years due to concerns about how well it works, and now Merck has to contend with patients possibly defecting to the generic versions of Pfizer Inc.'s Lipitor that came on the market at the end of November.
Merck said Monday that company officials will talk with the FDA to determine the next steps, adding that some new data expected later this year may address the FDA's concerns.
Wall Street seemed unfazed by the news, perhaps because the FDA increasingly asks for additional data before approving many new drugs. In morning trading, Merck shares were up 38 cents at $38.31.
The experimental drug, still known only as MK-0653C, contains medicines that fight high cholesterol in two different ways to reduce risk of heart attack and stroke.
Lipitor, known chemically as atorvastatin, is part of the widely used class of drugs called statins that reduce the amount of cholesterol naturally produced in the liver.
Zetia, on the other hand, reduces the amount of cholesterol absorbed from the food the patient eats.
Vytorin includes Zetia and an older statin, Merck's Zocor, also called simvastatin.
Sales of Vytorin and Zetia both were hurt when Merck, under pressure from a congressional probe, in early 2008 finally released unfavorable results from a study it had hoped would bolster Vytorin sales. Instead, it showed that Vytorin was no better at reducing plaque buildup in neck arteries than just Zocor, which had been available as a cheap generic since 2006. Zetia, also known as ezetimibe, is protected by patent in the U.S. until 2017.
Lipitor, which had peak sales of around $13 billion, is a more powerful statin then Zocor. That could mean that if the new combination drug is approved, it would be tried by at least some patients who have not been able to get their cholesterol numbers to their goal with Vytorin or other treatments.
Meanwhile, last year Lipitor maker Pfizer sued, alleging Merck's application for the FDA to approve the Zetia-atorvastatin combination infringed on a Pfizer patent covering atorvastatin.
A Merck spokeswoman said Monday that the lawsuit "has the potential for holding up FDA approval of the Merck product until" the first quarter of 2014.
Linda A. Johnson can be followed at http://twitter.com/LindaJ_onPharma
By Donald Lambro
Growth spikes are little more than trend-free anomalies
- Rand Paul: Budget deal 'shameful,' 'huge mistake'
- Teen thugs in D.C. run wild -- even while wearing GPS ankle bracelets
- Tea partiers turn on Capitol Hill budget deal
- Leon Panetta named as source of 'Zero Dark Thirty' scriptwriters information
- Biden guarantees victory on immigration reform
- Obama takes 'selfie' at Mandela's funeral service
- American bourbon now better than Scottish whisky: U.K.-born expert
- FENNO: Honestly, Mike Shanahan, why should we believe you now?
- CARSON: Why did the founders give us the Second Amendment?
- VEGAS RULES: Harry Reid pushed feds to change ruling for casino's big-money foreigners
Independent voices from the The Washington Times Communities
Interviews and show reviews from the Los Angeles punk scene past and present. Los Angeles has always been rich in punk rock talent since punk rock was born.
Buzz on Bees is a column promoting the love and life of God’s greatest pollinators on earth: The Honeybee
Brazen, leading-edge, “call it like it is” columns and reporting from Ohio native, radio host and writer, Sara Marie Brenner.
A libertarian look at breaking news and political trends by author Tom Mullen.
Extraordinary day at Redskins Park
White House pets gone wild!
Let it snow